Tumour necrosis factor-α inhibitors: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 21: | Line 21: | ||
* Baseline [[TST]], ±CXR, prior to starting medications, with patients identified as having [[LTBI]] being offered prophylaxis |
* Baseline [[TST]], ±CXR, prior to starting medications, with patients identified as having [[LTBI]] being offered prophylaxis |
||
** Cutoff for TST is 5 mm |
** Cutoff for TST is 5 mm |
||
| + | *Assess for [[hepatitis B prophylaxis]] |
||
=== Adverse Effects === |
=== Adverse Effects === |
||
| Line 28: | Line 29: | ||
* Bacteria: [[septic arthritis]], [[Listeria monocytogenes]], [[Legionella]], [[Nocardia]], [[Actinomyces]], [[Salmonella]] |
* Bacteria: [[septic arthritis]], [[Listeria monocytogenes]], [[Legionella]], [[Nocardia]], [[Actinomyces]], [[Salmonella]] |
||
* Mycobacteria: [[Mycobacterium tuberculosis|'''Mycobacterium tuberculosis''']], [[Mycobacterium avium]], [[Mycobacterium bovis]], BCG |
* Mycobacteria: [[Mycobacterium tuberculosis|'''Mycobacterium tuberculosis''']], [[Mycobacterium avium]], [[Mycobacterium bovis]], BCG |
||
| + | **Risk of TB is higher for [[infliximab]] and [[adalimumab]] compared to [[etanercept]] |
||
| − | * Fungi: [[Aspergillus fumigatus]], [[Histoplasma capsulatum]], [[Coccidioides]], [[Cryptococcus neoformans]], [[Candida albicans]] |
+ | * Fungi: [[Aspergillus fumigatus]], [[Histoplasma capsulatum|'''Histoplasma capsulatum''']], [[Coccidioides]], [[Cryptococcus neoformans]], [[Candida albicans]] |
* Parasites: [[Toxoplasma gondii]] |
* Parasites: [[Toxoplasma gondii]] |
||
| − | * Viruses: [[hepatitis B virus]], [[hepatitis C virus]], [[varicella-zoster virus]] |
+ | * Viruses: [[hepatitis B virus|'''hepatitis B virus''']], [[hepatitis C virus]], [[varicella-zoster virus]] |
* Screening prior to use should be done for [[LTBI]] (TST or IGRA), [[hepatitis B]], [[hepatitis C]], and [[HIV]] |
* Screening prior to use should be done for [[LTBI]] (TST or IGRA), [[hepatitis B]], [[hepatitis C]], and [[HIV]] |
||
Latest revision as of 20:40, 16 March 2022
Background
- TNF-α is a cytokine involved in the inflammatory response to infection
- Has soluble and transmembrane forms
- Produced by macrophages, NK cells, granulocytes, fibroblasts, and T cells
- Receptors for TNF-α (TNFR1 and TNFR2) are found on most human cells, and are involved in cell activation and proliferation, cytokine production, and granuloma formation
Medications
Contraindications
- Active bacterial infection, active tuberculosis or untreated LTBI, active herpes zoster infection, active invasive fungal infection, infected skin ulcers, acute hepatitis B or C, untreated chronic hepatitis B, or chronic hepatitis B or C with Child-Pugh B or C
Safety
- Baseline TST, ±CXR, prior to starting medications, with patients identified as having LTBI being offered prophylaxis
- Cutoff for TST is 5 mm
- Assess for hepatitis B prophylaxis
Adverse Effects
Infections
- Bacteria: septic arthritis, Listeria monocytogenes, Legionella, Nocardia, Actinomyces, Salmonella
- Mycobacteria: Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium bovis, BCG
- Risk of TB is higher for infliximab and adalimumab compared to etanercept
- Fungi: Aspergillus fumigatus, Histoplasma capsulatum, Coccidioides, Cryptococcus neoformans, Candida albicans
- Parasites: Toxoplasma gondii
- Viruses: hepatitis B virus, hepatitis C virus, varicella-zoster virus
- Screening prior to use should be done for LTBI (TST or IGRA), hepatitis B, hepatitis C, and HIV
